Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
9
43
20
14
18
19
Croissance des revenus (H/H)
-83%
114.99%
43%
-22%
-5%
73%
Coût des ventes
--
--
--
--
--
--
Bénéfice brut
--
--
--
--
--
--
Vente, Général et Administration
23
21
19
20
19
19
Recherche et développement
61
67
85
67
80
52
Frais d'exploitation
84
88
105
87
100
72
Autres revenus (charges) non opérationnels
4
4
11
7
6
9
Bénéfice avant impôts
-73
-43
-81
-64
-75
-44
Charge d'impôt sur le revenu
0
0
0
0
0
0
Bénéfice net
-73
-43
-81
-64
-75
-44
Croissance du bénéfice net
55%
-47%
27%
-15%
70%
2%
Actions en circulation (diluées)
12.54
12.53
9.45
65.51
32.83
26.04
Variation des actions (H-H)
0%
33%
-86%
100%
26%
2%
EPS (dilué)
-5.84
-3.46
-8.63
-0.99
-2.3
-1.69
Croissance du EPS
55%
-60%
772%
-56.99%
36%
1%
Flux de trésorerie libre
-52
-77
-61
-25
-78
-41
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
--
--
--
--
--
--
Marge opérationnelle
-822.22%
-102.32%
-420%
-521.42%
-450%
-278.94%
Marge bénéficiaire
-811.11%
-100%
-405%
-457.14%
-416.66%
-231.57%
Marge du flux de trésorerie libre
-577.77%
-179.06%
-305%
-178.57%
-433.33%
-215.78%
EBITDA
-72
-44
-84
-73
-81
-53
Marge EBITDA
-800%
-102.32%
-420%
-521.42%
-450%
-278.94%
D&A pour le résultat opérationnel
2
0
0
0
0
0
EBIT
-74
-44
-84
-73
-81
-53
Marge EBIT
-822.22%
-102.32%
-420%
-521.42%
-450%
-278.94%
Taux d'imposition effectif
0%
0%
0%
0%
0%
0%
Statistiques clés
Clôture préc.
$1.03
Prix d'ouverture
$1.01
Plage de la journée
$0.99 - $1.01
Plage de 52 semaines
$0.721 - $2.15
Volume
952
Volume moyen
23.1K
BPA (TTM)
-5.85
Rendement en dividend
--
Capitalisation boursière
$12.3M
Qu’est-ce que HOOK ?
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The company is headquartered in New York City, New York and currently employs 82 full-time employees. The company went IPO on 2019-04-18. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers.